Preferred Label : Anti-LLT1 Monoclonal Antibody ZM008;
NCIt synonyms : Anti-Lectin-like Transcript-1 Monoclonal Antibody ZM008;
NCIt definition : A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated
antigen (TAA) lectin-like transcript-1 (LLT1; CLEC2D; OCIL), with potential immunomodulating
and antineoplastic activities. Upon administration, anti-LLT1 monoclonal antibody
ZM008 targets and binds to LLT1 expressed on a variety of tumor cells. This prevents
the binding of LLT1 to its receptor C-type lectin-like receptor cluster of differentiation
161 (CD161) primarily expressed on CD161-positive natural killer (NK) cells. This
prevents CD161-mediated signaling, abrogates the CLEC2D/CD161-mediated suppression
of NK cells, leading to the activation and infiltration of NK cells and cytotoxic
T-cells in the tumor microenvironment (TME) and promotes anti-tumor immune response,
thereby enhancing cytotoxicity towards tumor cells. CD161, an inhibitory immune checkpoint,
is broadly expressed on NK and a subset of memory CD4 and CD8 T-cells. LLT1 is expressed
on the surface of both malignant cells and various immune cells, including activated
B-cells and myeloid cells. The interaction between LLT1 and CD161 leads to immune
repressive condition in the TME allowing tumor cells to bypass the human immune system.;
Molecule name : ZM 008; ZM-008;
Origin ID : C212125;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
